US2005192235A1PendingUtilityA1

Compositions and methods for treating or preventing diseases of body passageways

62
Assignee: UNIV BRITISH COLUMBIAPriority: May 24, 1996Filed: Oct 19, 2004Published: Sep 1, 2005
Est. expiryMay 24, 2016(expired)· nominal 20-yr term from priority
Inventors:William L. HunterLindsay Machan
A61P 9/00A61P 9/10A61P 35/00A61P 43/00A61P 31/06A61P 31/04A61P 27/02A61K 31/00A61K 9/1635A61K 9/10A61K 31/28A61P 11/08A61K 9/5192A61K 9/5138A61K 31/335A61K 9/70A61K 9/1652A61K 9/167A61K 9/1075A61P 13/08A61K 9/5031A61K 31/337A61K 9/1647A61P 15/00A61P 1/00A61K 9/0024A61K 9/12A61P 13/00A61P 13/02A61K 47/34A61K 9/7007A61K 9/5146A61P 1/04A61K 9/5153A61P 11/00A61K 33/24
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides methods for treating or preventing diseases associated with body passageways, comprising the step of delivering to an external portion of the body passageway a therapeutic agent. Representative examples of therapeutic agents include anti-angiogenic factors, anti-proliferative agents, anti-inflammatory agents, and antibiotics.

Claims

exact text as granted — not AI-modified
1 . A method for treating or preventing a vascular disease associated with graft anastomosis, comprising delivering to an external portion of the site of graft anastomosis a therapeutically effective amount of a therapeutic agent or a composition comprising a therapeutic agent, such that the vascular disease is treated.  
     
     
         2 . The method of  claim 1  wherein the vascular disease is stenosis.  
     
     
         3 . The method of  claim 1  wherein the vascular disease is restenosis.  
     
     
         4 . The method of  claim 1  wherein the vascular disease is atherosclerosis.  
     
     
         5 . The method of  claim 1  wherein the site of graft anastomosis is an artery.  
     
     
         6 . The method of  claim 5  wherein the artery is a carotid artery.  
     
     
         7 . The method of  claim 1  wherein the site of graft anastomosis is a vein.  
     
     
         8 . The method of  claim 1  wherein the graft anastomosis a distal anastamosis.  
     
     
         9 . The method of  claim 1  wherein the graft anastomosis a proximal anastamosis.  
     
     
         10 . The method of  claim 1  wherein the therapeutic agent is an anti-angiogenic factor.  
     
     
         11 . The method of  claim 1  wherein the therapeutic agent is a compound which disrupts microtubule function.  
     
     
         12 . The method of  claim 1  wherein the therapeutic agent is an inhibitor of platelet adhesion or aggregation.  
     
     
         13 . The method of  claim 1  wherein the therapeutic agent is a vasodilator.  
     
     
         14 . The method of  claim 1  wherein the therapeutic agent is an anti-inflammatory agent.  
     
     
         15 . The method of  claim 1  wherein the therapeutic agent is an immunosuppressive agent.  
     
     
         16 . The method of  claim 1  wherein the therapeutic agent is a growth factor inhibitor.  
     
     
         17 . The method of  claim 1  wherein the therapeutic agent is a promoter of re-endothelialization.  
     
     
         18 . The method of  claim 1  wherein the therapeutic agent is mitoxantrone.  
     
     
         19 . The method of  claim 1  wherein the therapeutic agent is a metalloproteinase inhibitor.  
     
     
         20 . The method of  claim 1  wherein the therapeutic agent is angiostatin.  
     
     
         21 . The method of  claim 1  wherein the therapeutic agent is an anthracycline.  
     
     
         22 . The method of  claim 1  wherein the therapeutic agent is estradiol.  
     
     
         23 . The method of  claim 1  wherein the therapeutic agent is carboplatin.  
     
     
         24 . The method of  claim 1  wherein the therapeutic agent is doxorubicin.  
     
     
         25 . The method of  claim 1  wherein the therapeutic agent is 5-fluorouracil.  
     
     
         26 . The method of  claim 1  wherein the composition is biodegradable.  
     
     
         27 . The method of  claim 1  wherein the composition is non-biodegradable.  
     
     
         28 . The method of  claim 1  wherein the composition further comprises a polymer.  
     
     
         29 . The method of  claim 28  wherein the polymer is biodegradable.  
     
     
         30 . The method of  claim 28  wherein the polymer is non-biodegradable.  
     
     
         31 . The method of  claim 1  wherein the composition further comprises a copolymer of lactic acid and glycolic acid.  
     
     
         32 . The method of  claim 1  wherein the composition further comprises a poly(caprolactone).  
     
     
         33 . The method of  claim 1  wherein the composition further comprises a poly(lactic acid).  
     
     
         34 . The method of  claim 1  wherein the composition further comprises a copolymer of poly(lactic acid) and poly(caprolactone).  
     
     
         35 . The method of  claim 1  wherein the composition further comprises a poly(ethylene-vinyl acetate).  
     
     
         36 . The method of  claim 1  wherein the composition further comprises a polyester.  
     
     
         37 . The method of  claim 1  wherein the composition further comprises a polyurethane.  
     
     
         38 . The method of  claim 1  wherein the composition further comprises a polyanhydride.  
     
     
         39 . The method of  claim 1  wherein the composition further comprises a gelatin.  
     
     
         40 . The method of  claim 1  wherein the composition is in the form of a paste.  
     
     
         41 . The method of  claim 1  wherein the composition is in the form of a film.  
     
     
         42 . The method of  claim 1  wherein the composition is in the form of a spray.  
     
     
         43 . The method of  claim 1  wherein the composition comprises microspheres having an average size ranging from about 0.5 μm to 200 μm.  
     
     
         44 . The method of  claim 1  wherein the graft is a PTFE graft.  
     
     
         45 . The method of  claim 1  wherein the therapeutic agent or the composition comprising the therapeutic agent is administered percutaneously to the exterior surface of the site of graft anastomosis.  
     
     
         46 . The method of  claim 1  wherein the therapeutic agent or the composition comprising the therapeutic agent is applied to the adventitial surface of the site of graft anastomosis.  
     
     
         47 . The method of  claim 46  wherein the composition is in the form of a film.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.